Microbiome Therapeutics Market
Microbiome Therapeutics Market Forecasts to 2034 - Global Analysis By Product Type (Probiotics-based Therapeutics, Prebiotics-based Therapeutics, Synbiotics, Fecal Microbiota Transplantation (FMT) and Live Biotherapeutic Products (LBPs) ), Route of Administration, Technology, Application, End User and By Geography
According to Stratistics MRC, the Global Microbiome Therapeutics Market is accounted for $9.6 billion in 2026 and is expected to reach $31.2 billion by 2034 growing at a CAGR of 15.8% during the forecast period. Microbiome therapeutics refer to biological interventions designed to modulate the composition and function of the human microbiome the complex community of microorganisms inhabiting the gut, skin, respiratory tract, and other body sites to prevent, treat, or manage disease conditions. They encompass live biotherapeutic products, probiotics, prebiotics, synbiotics, and fecal microbiota transplantation formulations. These therapeutics target inflammatory bowel disease, Clostridioides difficile infections, metabolic disorders, oncology indications, and neuropsychiatric conditions by restoring dysbiotic microbial ecosystems.
Market Dynamics:
Driver:
Rising Gut Disorder Prevalence
Rising global prevalence of inflammatory bowel disease, irritable bowel syndrome, and Clostridioides difficile infections is a primary driver compelling pharmaceutical investment in microbiome therapeutic solutions. Conventional antibiotic and immunosuppressive treatment limitations create unmet clinical needs that microbiome-based interventions are positioned to address with disease-modifying rather than symptom-suppressing mechanisms. FDA approval frameworks for live biotherapeutic products are maturing, accelerating commercial pipeline investment and generating late-stage clinical programs across major gastrointestinal and systemic disease indications.
Restraint:
Manufacturing Standardization Complexity
Manufacturing standardization complexity represents a critical barrier as live biotherapeutic products and fecal microbiota transplantation formulations require consistent microbial community composition across production batches — a challenge that current GMP frameworks and quality control assay infrastructure are still evolving to address. Strain viability maintenance during manufacturing, formulation, and cold-chain distribution imposes substantial operational complexity. Regulatory divergence between the United States, Europe, and Asia Pacific on live biotherapeutic product classification creates parallel submission burdens that disproportionately impact smaller microbiome therapeutic developers.
Opportunity:
Oncology Microbiome Modulation
Oncology microbiome modulation presents a transformative commercial opportunity as clinical evidence accumulates demonstrating that gut microbiome composition significantly influences cancer immunotherapy response rates and treatment toxicity profiles. Live biotherapeutic products designed to optimize anti-tumor immune responses in combination with checkpoint inhibitor regimens are generating compelling early clinical data. Pharmaceutical companies are forming strategic partnerships with microbiome platform developers to incorporate microbiome modulation as a standard component of cancer immunotherapy protocols across melanoma, lung cancer, and other solid tumor indications.
Threat:
Competitive Probiotic Consumer Products
Competitive pricing pressure from consumer probiotic products creates a reimbursement and positioning challenge for clinical microbiome therapeutics, as physicians and patients may perceive commercial probiotic supplements as equivalent alternatives to prescription-grade live biotherapeutic products at substantially lower cost. Differentiating clinical-grade microbiome therapeutics from consumer wellness products requires sustained physician education investment and robust comparative clinical trial evidence. Regulatory agencies face definitional challenges distinguishing food-grade from drug-grade microbiome interventions, creating compliance ambiguity that complicates market positioning.
Covid-19 Impact:
COVID-19 research identified significant associations between gut microbiome dysbiosis and COVID-19 disease severity and long-COVID symptom persistence, generating substantial scientific and investor interest in microbiome therapeutic interventions. Pandemic-era research programs evaluating microbiome modulation for respiratory infection resilience have expanded the recognized therapeutic application scope. Post-pandemic, accelerated microbiome research investment and regulatory agency engagement have shortened development timelines for leading live biotherapeutic product candidates.
The live biotherapeutic products (LBPs) segment is expected to be the largest during the forecast period
The live biotherapeutic products (LBPs) segment is expected to account for the largest market share during the forecast period, due to FDA and EMA recognition of LBPs as a distinct pharmaceutical category with defined regulatory pathways, enabling investment-grade clinical development programs. Multiple LBP candidates addressing C. difficile infection, inflammatory bowel disease, and oncology indications are in Phase II and Phase III clinical stages. Strong clinical evidence differentiation from general probiotics and clear reimbursement pathway visibility are attracting sustained pharmaceutical industry investment in the segment.
The oral segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the oral segment is predicted to witness the highest growth rate, driven by patient preference for non-invasive delivery formats and pharmaceutical investment in next-generation encapsulation technologies that protect live microbiome formulations from gastric acid degradation. Oral delivery enables outpatient self-administration, substantially expanding addressable patient populations beyond hospital-administered fecal microbiota transplantation procedures. Advancements in enteric coating technologies and spore-forming organism formulations are improving oral LBP clinical performance, generating positive regulatory interactions supporting product approvals.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, due to FDA regulatory leadership in establishing live biotherapeutic product approval frameworks, concentration of microbiome biotechnology companies, and substantial venture capital investment in the sector. The United States hosts the highest density of clinical-stage microbiome therapeutic programs globally. High gastrointestinal disease prevalence, well-developed specialty pharmaceutical reimbursement infrastructure, and leading academic microbiome research institutions sustain North America's commercial ecosystem dominance.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to expanding biotechnology investment in China, Japan, and South Korea, growing awareness of gut health therapeutics, and large patient populations with gastrointestinal disorders. Government-funded microbiome research initiatives across Asia Pacific are building clinical trial infrastructure and regulatory competency that are attracting international pharmaceutical partnerships. Cultural integration of probiotic and fermented food traditions creates consumer openness to microbiome-based therapeutic concepts that accelerates prescription adoption.
Key players in the market
Some of the key players in Microbiome Therapeutics Market include Seres Therapeutics, Ferring Pharmaceuticals, Enterome, Second Genome, Rebiotix, 4D Pharma, Vedanta Biosciences, Synlogic, BiomeBank, Yakult Honsha, Nestlé Health Science, Danone, DuPont (IFF), Probi AB, Chr. Hansen, Novozymes, Optibiotix Health, and Evelo Biosciences.
Key Developments:
In March 2026, Seres Therapeutics initiated a Phase II combination study evaluating its microbiome therapeutic alongside pembrolizumab for solid tumor indications including non-small cell lung cancer.
In February 2026, Synlogic advanced its engineered probiotic candidate for phenylketonuria into Phase III pivotal trials following positive interim metabolic control endpoint data.
In January 2026, Ferring Pharmaceuticals received expanded FDA approval for its live biotherapeutic product REBYOTA covering additional C. difficile recurrence prevention indications in immunocompromised patients.
In November 2025, Vedanta Biosciences reported positive Phase II efficacy data for its defined bacterial consortium LBP targeting ulcerative colitis remission induction in moderate-to-severe patients.
Product Types Covered:
• Probiotics-based Therapeutics
• Prebiotics-based Therapeutics
• Synbiotics
• Fecal Microbiota Transplantation (FMT)
• Live Biotherapeutic Products (LBPs)
Route of Administrations Covered:
• Oral
• Rectal
• Topical
• Others
Technologies Covered:
• Microbiome Sequencing Technologies
• Metagenomics & Bioinformatics
• Genetic Engineering of Microbes
• Drug Delivery Technologies
• AI-driven Microbiome Analysis
Applications Covered:
• Gastrointestinal Disorders
• Metabolic Disorders
• Infectious Diseases
• Neurological Disorders
• Oncology
End Users Covered:
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Research Institutes
• Contract Research Organizations
• Other End Userz
Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
§ Saudi Arabia
§ United Arab Emirates
§ Qatar
§ Israel
§ Rest of Middle East
o Africa
§ South Africa
§ Egypt
§ Morocco
§ Rest of Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Microbiome Therapeutics Market, By Product Type
5.1 Probiotics-based Therapeutics
5.1.1 Single-Strain Probiotics
5.1.2 Multi-Strain Probiotics
5.1.3 Next-Generation Probiotics
5.2 Prebiotics-based Therapeutics
5.2.1 Oligosaccharides
5.2.2 Dietary Fibers
5.3 Synbiotics
5.4 Fecal Microbiota Transplantation (FMT)
5.5 Live Biotherapeutic Products (LBPs)
6 Global Microbiome Therapeutics Market, By Route of Administration
6.1 Oral
6.2 Rectal
6.3 Topical
6.4 Others
7 Global Microbiome Therapeutics Market, By Technology
7.1 Microbiome Sequencing Technologies
7.2 Metagenomics & Bioinformatics
7.3 Genetic Engineering of Microbes
7.4 Drug Delivery Technologies
7.5 AI-driven Microbiome Analysis
8 Global Microbiome Therapeutics Market, By Application
8.1 Gastrointestinal Disorders
8.1.1 Inflammatory Bowel Disease (IBD)
8.1.2 Irritable Bowel Syndrome (IBS)
8.2 Metabolic Disorders
8.2.1 Obesity
8.2.2 Diabetes
8.3 Infectious Diseases
8.4 Neurological Disorders
8.5 Oncology
9 Global Microbiome Therapeutics Market, By End User
9.1 Hospitals & Clinics
9.2 Pharmaceutical & Biotechnology Companies
9.3 Research Institutes
9.4 Contract Research Organizations
9.5 Other End Userz
10 Global Microbiome Therapeutics Market, By Geography
10.1 North America
10.1.1 United States
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 United Kingdom
10.2.2 Germany
10.2.3 France
10.2.4 Italy
10.2.5 Spain
10.2.6 Netherlands
10.2.7 Belgium
10.2.8 Sweden
10.2.9 Switzerland
10.2.10 Poland
10.2.11 Rest of Europe
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Australia
10.3.6 Indonesia
10.3.7 Thailand
10.3.8 Malaysia
10.3.9 Singapore
10.3.10 Vietnam
10.3.11 Rest of Asia Pacific
10.4 South America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Colombia
10.4.4 Chile
10.4.5 Peru
10.4.6 Rest of South America
10.5 Rest of the World (RoW)
10.5.1 Middle East
10.5.1.1 Saudi Arabia
10.5.1.2 United Arab Emirates
10.5.1.3 Qatar
10.5.1.4 Israel
10.5.1.5 Rest of Middle East
10.5.2 Africa
10.5.2.1 South Africa
10.5.2.2 Egypt
10.5.2.3 Morocco
10.5.2.4 Rest of Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Seres Therapeutics
12.2 Ferring Pharmaceuticals
12.3 Enterome
12.4 Second Genome
12.5 Rebiotix
12.6 4D Pharma
12.7 Vedanta Biosciences
12.8 Synlogic
12.9 BiomeBank
12.10 Yakult Honsha
12.11 Nestlé Health Science
12.12 Danone
12.13 DuPont (IFF)
12.14 Probi AB
12.15 Chr. Hansen
12.16 Novozymes
12.17 Optibiotix Health
12.18 Evelo Biosciences
List of Tables
1 Global Microbiome Therapeutics Market Outlook, By Region (2023-2034) ($MN)
2 Global Microbiome Therapeutics Market Outlook, By Product Type (2023-2034) ($MN)
3 Global Microbiome Therapeutics Market Outlook, By Probiotics-based Therapeutics (2023-2034) ($MN)
4 Global Microbiome Therapeutics Market Outlook, By Single-Strain Probiotics (2023-2034) ($MN)
5 Global Microbiome Therapeutics Market Outlook, By Multi-Strain Probiotics (2023-2034) ($MN)
6 Global Microbiome Therapeutics Market Outlook, By Next-Generation Probiotics (2023-2034) ($MN)
7 Global Microbiome Therapeutics Market Outlook, By Prebiotics-based Therapeutics (2023-2034) ($MN)
8 Global Microbiome Therapeutics Market Outlook, By Oligosaccharides (2023-2034) ($MN)
9 Global Microbiome Therapeutics Market Outlook, By Dietary Fibers (2023-2034) ($MN)
10 Global Microbiome Therapeutics Market Outlook, By Synbiotics (2023-2034) ($MN)
11 Global Microbiome Therapeutics Market Outlook, By Fecal Microbiota Transplantation (FMT) (2023-2034) ($MN)
12 Global Microbiome Therapeutics Market Outlook, By Live Biotherapeutic Products (LBPs) (2023-2034) ($MN)
13 Global Microbiome Therapeutics Market Outlook, By Route of Administration (2023-2034) ($MN)
14 Global Microbiome Therapeutics Market Outlook, By Oral (2023-2034) ($MN)
15 Global Microbiome Therapeutics Market Outlook, By Rectal (2023-2034) ($MN)
16 Global Microbiome Therapeutics Market Outlook, By Topical (2023-2034) ($MN)
17 Global Microbiome Therapeutics Market Outlook, By Others (2023-2034) ($MN)
18 Global Microbiome Therapeutics Market Outlook, By Technology (2023-2034) ($MN)
19 Global Microbiome Therapeutics Market Outlook, By Microbiome Sequencing Technologies (2023-2034) ($MN)
20 Global Microbiome Therapeutics Market Outlook, By Metagenomics & Bioinformatics (2023-2034) ($MN)
21 Global Microbiome Therapeutics Market Outlook, By Genetic Engineering of Microbes (2023-2034) ($MN)
22 Global Microbiome Therapeutics Market Outlook, By Drug Delivery Technologies (2023-2034) ($MN)
23 Global Microbiome Therapeutics Market Outlook, By AI-driven Microbiome Analysis (2023-2034) ($MN)
24 Global Microbiome Therapeutics Market Outlook, By Application (2023-2034) ($MN)
25 Global Microbiome Therapeutics Market Outlook, By Gastrointestinal Disorders (2023-2034) ($MN)
26 Global Microbiome Therapeutics Market Outlook, By Inflammatory Bowel Disease (IBD) (2023-2034) ($MN)
27 Global Microbiome Therapeutics Market Outlook, By Irritable Bowel Syndrome (IBS) (2023-2034) ($MN)
28 Global Microbiome Therapeutics Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
29 Global Microbiome Therapeutics Market Outlook, By Obesity (2023-2034) ($MN)
30 Global Microbiome Therapeutics Market Outlook, By Diabetes (2023-2034) ($MN)
31 Global Microbiome Therapeutics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
32 Global Microbiome Therapeutics Market Outlook, By Neurological Disorders (2023-2034) ($MN)
33 Global Microbiome Therapeutics Market Outlook, By Oncology (2023-2034) ($MN)
34 Global Microbiome Therapeutics Market Outlook, By End User (2023-2034) ($MN)
35 Global Microbiome Therapeutics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
36 Global Microbiome Therapeutics Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
37 Global Microbiome Therapeutics Market Outlook, By Research Institutes (2023-2034) ($MN)
38 Global Microbiome Therapeutics Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
39 Global Microbiome Therapeutics Market Outlook, By Other End Userz (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
